<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621137</url>
  </required_header>
  <id_info>
    <org_study_id>TREAT NL registry</org_study_id>
    <nct_id>NCT03621137</nct_id>
  </id_info>
  <brief_title>TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies</brief_title>
  <acronym>TREAT NL</acronym>
  <official_title>TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TREAT NL (TREatment of ATopic eczema, the Netherlands) registry is a national registry
      for children and adults with moderate-to-severe atopic eczema aiming to gather data on their
      prescribed photo- and systemic immunomodulating therapies. Atopic eczema is a common,
      chronic, itchy, inflammatory skin disease that can have a major impact on the quality of life
      of patients and their immediate surroundings.

      Serious atopic eczema patients are treated by means of photo- or systemic immunomodulating
      therapy. Of these mostly off-label applied therapies, there is insufficient evidence on the
      short and long term for their effectiveness, safety and cost-effectiveness. Moreover, good
      comparative research and real-life data are lacking. With the arrival of new expensive
      treatments it is crucial to get insight into these treatments in order to improve quality of
      care.

      By means of a prospective registry these data can be collected and help to obtain information
      for clinical practice, for answering research questions, for reducing costs and implementing
      the results by guidelines and decision aids.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Mean change in EASI (Eczema Area and Severity Index) score</measure>
    <time_frame>5 years</time_frame>
    <description>Investigator-assessed outcome measure for disease severity at physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in IGA (Investigator's Global Assessment) score</measure>
    <time_frame>5 years</time_frame>
    <description>Investigator-assessed outcome measure for global disease severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in POEM (Patient-Oriented Eczema Measure) score</measure>
    <time_frame>5 years</time_frame>
    <description>Patient-reported outcome measure for symptoms of atopic eczema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in PGA (Patient's Global Assessment) score</measure>
    <time_frame>5 years</time_frame>
    <description>Patient-reported outcome measure for global disease severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in DLQI (Dermatology Life Quality Index) score</measure>
    <time_frame>5 years</time_frame>
    <description>Patient-reported outcome measure for skin-related quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time to reach a change in EASI (Eczema Area and Severity Index) score of 50%</measure>
    <time_frame>5 years</time_frame>
    <description>Investigator-assessed outcome measure for disease severity at physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of severe adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Any undesirable experience of severe nature occurring to a subject is reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug survival of the therapies</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment of the duration until discontinuation of a drug together with the reason thereof</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Moderate-to-severe Atopic Eczema</condition>
  <arm_group>
    <arm_group_label>Patients with moderate-to-severe atopic eczema</arm_group_label>
    <description>Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No study-specific intervention</intervention_name>
    <description>Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice</description>
    <arm_group_label>Patients with moderate-to-severe atopic eczema</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      TREAT NL biobank substudy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients of participating centres that meet the predefined in- and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a diagnosis of atopic eczema, based on the U.K. working party's diagnostic
             criteria;

          -  Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy
             (e.g. cyclosporin, systemic glucocorticosteroids, azathioprine, methotrexate,
             mycophenolic acid, dupilumab);

          -  Has voluntarily signed and dated an informed consent prior to any study related
             procedure or has a legal representative to do so and is willing to comply with the
             requirements of this study protocol.

        Exclusion Criteria:

          -  Patient uses only (systemic) antibiotics or antihistamines;

          -  Patient starts with systemic immunomodulating therapy for another indication than
             atopic eczema;

          -  Insufficient understanding of the study by the patient or parent/legal representative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis I. Spuls, prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela L. Bosma</last_name>
    <phone>+31205662757</phone>
    <email>a.l.bosma@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AriÃ«nna M. Hyseni</last_name>
    <phone>+31205662481</phone>
    <email>a.m.hyseni@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Amsterdam University Medical Centres, University of Amsterdam, Research Institute Amsterdam Public Health and Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands</name>
      <address>
        <city>Amsterdam</city>
        <state>North-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Bosma</last_name>
    </contact>
    <contact_backup>
      <last_name>Priscella Eppenga</last_name>
    </contact_backup>
    <investigator>
      <last_name>Phyllis Spuls, prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pina Middelkamp Hup, dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Gerbens, dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Bosma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Priscella Eppenga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://treat-registry-taskforce.org/</url>
    <description>Website of the international TREAT Registry Taskforce</description>
  </link>
  <reference>
    <citation>Gerbens LA, Boyce AE, Wall D, Barbarot S, de Booij RJ, Deleuran M, Middelkamp-Hup MA, Roberts A, Vestergaard C, Weidinger S, Apfelbacher CJ, Irvine AD, Schmitt J, Williamson PR, Spuls PI, Flohr C. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials. 2017 Feb 27;18(1):87. doi: 10.1186/s13063-016-1765-7.</citation>
    <PMID>28241851</PMID>
  </reference>
  <reference>
    <citation>Spuls PI, Gerbens LAA, Apfelbacher CJ, Wall D, Arents BWM, Barbarot S, Roberts A, Deleuran M, Middelkamp-Hup MA, Vestergaard C, Weidinger S, Schmitt J, Irvine AD, Flohr C. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. J Invest Dermatol. 2017 Sep;137(9):2014-2016. doi: 10.1016/j.jid.2017.05.014. Epub 2017 May 27.</citation>
    <PMID>28558913</PMID>
  </reference>
  <reference>
    <citation>Gerbens LAA, Apfelbacher CJ, Irvine AD, Barbarot S, de Booij RJ, Boyce AE, Deleuran M, Eichenfield LF, Hof MH, Middelkamp-Hup MA, Roberts A, Schmitt J, Vestergaard C, Wall D, Weidinger S, Williamson PR, Flohr C, Spuls PI; international TREAT Registry Taskforce. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. Br J Dermatol. 2019 Apr;180(4):790-801. doi: 10.1111/bjd.16714. Epub 2018 Aug 3.</citation>
    <PMID>29761486</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Angela Bosma</investigator_full_name>
    <investigator_title>Co-investigator</investigator_title>
  </responsible_party>
  <keyword>Atopic Eczema</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Registries</keyword>
  <keyword>Systemic therapies</keyword>
  <keyword>Off-label use</keyword>
  <keyword>Phototherapy</keyword>
  <keyword>Child</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

